H

Hospital Nossa Senhora da Conceicao | Conceicao Hospital - Infectious Diseases Department

Research site
(Unclaimed)
Location
Av. Francisco Trein, 596 Porto, Porto Alegre, Rio Grande do Sul, Brazil

Site insights

Top conditions

Top treatments

Atezolizumab
Trastuzumab
Pertuzumab
Paclitaxel
Bevacizumab
Prednisone
Cyclophosphamide
Pembrolizumab
Doxorubicin
Tiragolumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

26 of 57 total trials

A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (CUPISCO)

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with p...

Active, not recruiting
Cancer of Unknown Primary Site
Drug: Pemigatinib
Drug: Entrectinib
Recently updated

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine...

Enrolling
Neoplasm Metastasis
Drug: Trastuzumab
Drug: Pertuzumab

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Enrolling
Breast Cancer
Drug: Trastuzumab Emtansine
Drug: Placebo

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with elig...

Enrolling
Non-Small Cell Lung Cancer
Drug: Durvalumab
Drug: Entrectinib

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in pa...

Enrolling
Non-Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Carboplatin

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and...

Active, not recruiting
Small Cell Lung Cancer
Drug: Carboplatin
Drug: Tiragolumab

This is a global Phase III, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of adjuvant treatment wit...

Enrolling
Muscle-invasive Bladder Cancer
Drug: Atezolizumab
Other: Placebo

This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment w...

Active, not recruiting
Non-Small-Cell Lung
Drug: Pemetrexed
Drug: Nab-paclitaxel

This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemot...

Enrolling
Nasopharyngeal Carcinoma
Drug: placebo
Drug: Penpulimab

This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperabl...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Placebo
Drug: Capecitabine

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed a...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Drug: Pemetrexed
Drug: Atezolizumab

The purpose of this study is to evaluate the efficacy and safety of tiragolumab in combination with atezolizumab and atezolizumab monotherapy in pati...

Active, not recruiting
Cervical Cancer
Drug: Atezolizumab
Drug: Tiragolumab

The purpose of this study is to assess the efficacy and safety of a novel immunotherapy candidate, tobemstomig, in combination with nab-paclitaxel, f...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Tobemstomig

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based che...

Enrolling
Non-small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Paclitaxel

This study will evaluate the efficacy, safety and patient-reported outcomes of trastuzumab emtansine plus atezolizumab compared with trastuzumab emta...

Active, not recruiting
Metastatic Breast Cancer
Other: Placebo
Drug: Atezolizumab

This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in pat...

Active, not recruiting
Breast Cancer
Drug: trastuzumab
Drug: trastuzumab emtansine

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Enrolling
Cutaneous Squamous Cell Carcinoma
Drug: INCB099280

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumor...

Enrolling
Advanced Solid Tumor
Drug: INCB099280

This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two popula...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Atezolizumab

This is a Phase IIIb, multinational, multicenter, randomized, open-label study to evaluate patient preference of the fixed-dose combination of pertuz...

Active, not recruiting
Locally Advanced Breast Cancer
Inflammatory Breast Cancer
Drug: Trastuzumab Emtansine
Procedure: Surgery

Trial sponsors

Roche logo
Incyte logo
H
Celgene logo
Genentech logo
A
Akeso logo
Amgen logo
Eisai logo
Immunocore logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems